https://www.immunocore.com/ https://www.immunocore.com/about-us https://www.immunocore.com/about-us/management-team https://www.immunocore.com/about-us/board-of-directors https://www.immunocore.com/about-us/compliance-and-transparency https://www.immunocore.com/pipeline-portfolio/pipeline https://www.immunocore.com/pipeline-portfolio/our-therapies https://www.immunocore.com/science https://www.immunocore.com/science/publications https://www.immunocore.com/science/human-leukocyte-antigen-system https://www.immunocore.com/clinical-trials https://www.immunocore.com/investors https://www.immunocore.com/investors/news/press-releases https://www.immunocore.com/investors/news/email-alerts https://www.immunocore.com/investors/events-presentations/events https://www.immunocore.com/investors/events-presentations/presentations https://www.immunocore.com/investors/stock-info/quote-and-chart https://www.immunocore.com/investors/stock-info/historical-performance https://www.immunocore.com/investors/stock-info/analyst-coverage https://www.immunocore.com/investors/financials-filings/financial-results https://www.immunocore.com/investors/financials-filings/sec-filings https://www.immunocore.com/investors/financials-filings/annual-reports https://www.immunocore.com/investors/financials-filings/email-alerts https://www.immunocore.com/investors/corporate-governance https://www.immunocore.com/investors/corporate-governance/governance-documents https://www.immunocore.com/investors/corporate-governance/management-team https://www.immunocore.com/investors/corporate-governance/board-committees https://www.immunocore.com/investors/ir-resources/investor-faqs https://www.immunocore.com/investors/ir-resources/email-alerts https://www.immunocore.com/investors/ir-resources/contacts https://www.immunocore.com/medical-information https://www.immunocore.com/medical-information/us-healthcare-professionals https://www.immunocore.com/medical-information/uk-healthcare-professionals https://www.immunocore.com/investors/news/press-releases/detail/127/immunocore-will-present-five-year-overall-survival-data-for-kimmtrak-during-oral-presentation-at-the-2026-aacr-meeting https://www.immunocore.com/investors/news/press-releases/detail/126/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/125/immunocore-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/124/immunocore-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-call-on-february-25-2026 https://www.immunocore.com/investors/news/press-releases/detail/123/immunocore-announces-rd-leadership-evolution https://www.immunocore.com/investors/news/press-releases/detail/122/immunocore-announces-2026-strategic-priorities-at-44th-annual-j-p-morgan-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/121/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/120/immunocore-presents-phase-1-data-for-hepatitis-b-candidate-at-aaslds-the-liver-meeting https://www.immunocore.com/investors/news/press-releases/detail/119/immunocore-reports-third-quarter-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/118/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/117/immunocore-reports-second-quarter-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/116/immunocore-to-report-second-quarter-2025-financial-results-and-host-call-on-august-7-2025 https://www.immunocore.com/investors/news/press-releases/detail/115/immunocore-to-present-at-the-2025-jefferies-global-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/114/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/113/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/112/immunocore-presents-initial-multiple-ascending-dose-data-for-hiv-functional-cure-candidate-in-an-oral-presentation-at-croi-2025 https://www.immunocore.com/investors/news/press-releases/detail/111/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/110/immunocore-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/109/immunocore-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-call-on-february-26-2025 https://www.immunocore.com/investors/news/press-releases/detail/108/immunocore-announces-strategic-priorities-at-43rd-annual-j-p-morgan-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/107/immunocore-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/106/immunocore-appoints-travis-coy-previously-a-non-executive-director-as-its-evp-chief-financial-officer-and-head-of-corporate-development https://www.immunocore.com/investors/news/press-releases/detail/105/immunocore-announces-first-patient-dosed-in-the-phase-1-trial-of-imc-p115c-a-half-life-extended-hle-immtac-candidate-in-patients-with-tumors-that-express-prame https://www.immunocore.com/investors/news/press-releases/detail/104/immunocore-announces-dosing-of-first-patient-in-the-phase-12-trial-of-imc-r117c-targeting-piwil1-in-advanced-gastrointestinal-cancers https://www.immunocore.com/investors/news/press-releases/detail/103/eortc-and-immunocore-announce-enrolment-of-first-patient-onto-the-only-active-phase-3-adjuvant-trial-in-uveal-melanoma https://www.immunocore.com/investors/news/press-releases/detail/102/immunocore-announces-reimbursement-agreement-in-england-for-kimmtrak-for-the-treatment-of-hla-a02-01-positive-adults-with-unresectable-or-metastatic-uveal-melanoma https://www.immunocore.com/investors/news/press-releases/detail/101/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/100/immunocore-reports-third-quarter-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/99/immunocore-presents-phase-1-data-of-brenetafusp-an-immtac-bispecific-targeting-prame-in-patients-with-ovarian-cancer https://www.immunocore.com/investors/news/press-releases/detail/98/immunocore-to-present-at-the-2024-cantor-global-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/97/immunocore-announces-transition-of-chief-financial-officer https://www.immunocore.com/investors/news/press-releases/detail/96/immunocore-reports-second-quarter-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/95/immunocore-to-report-second-quarter-2024-financial-results-and-host-call-on-august-8-2024 https://www.immunocore.com/investors/news/press-releases/detail/94/immunocore-announces-randomization-of-first-patient-in-the-global-registrational-phase-3-clinical-trial-testing-brenetafusp-for-the-treatment-of-first-line-advanced-or-metastatic-cutaneous-melanoma https://www.immunocore.com/investors/news/press-releases/detail/93/immunocore-presents-kimmtrak-clinical-data-demonstrating-that-patients-with-stable-disease-and-confirmed-tumor-reduction-have-similar-clinical-outcomes-to-patients-with-partial-response https://www.immunocore.com/investors/news/press-releases/detail/92/immunocore-reports-updated-phase-1-data-of-brenetafusp-imc-f106c-an-immtac-bispecific-targeting-prame-in-immune-checkpoint-pre-treated-cutaneous-melanoma-patients-at-asco-2024 https://www.immunocore.com/investors/news/press-releases/detail/91/immunocore-to-present-at-the-jefferies-global-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/90/immunocore-converts-phase-23-tebe-am-clinical-trial-into-registrational-phase-3-trial-evaluating-kimmtrak-for-previously-treated-advanced-cutaneous-melanoma https://www.immunocore.com/investors/news/press-releases/detail/89/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/88/immunocore-announces-upcoming-presentation-and-posters-at-asco-2024 https://www.immunocore.com/investors/news/press-releases/detail/87/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/86/immunocore-presented-two-posters-at-croi-2024 https://www.immunocore.com/investors/news/press-releases/detail/85/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/84/immunocore-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-a-business-update https://www.immunocore.com/investors/news/press-releases/detail/83/immunocore-announces-clinical-trial-collaboration-and-supply-agreement-with-bristol-myers-squibb-to-evaluate-imc-f106c-prame-hla-a02-in-combination-with-nivolumab-in-its-registrational-phase-3-first-line-advanced-cutaneous-melanoma-trial https://www.immunocore.com/investors/news/press-releases/detail/82/immunocore-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-call-on-february-28-2024 https://www.immunocore.com/investors/news/press-releases/detail/81/immunocore-prices-upsized-convertible-senior-notes-offering https://www.immunocore.com/investors/news/press-releases/detail/80/immunocore-announces-proposed-convertible-senior-notes-offering https://www.immunocore.com/investors/news/press-releases/detail/79/immunocore-announces-strategic-priorities-and-pipeline-expansion-ahead-of-42nd-annual-j-p-morgan-healthcare-conference-presentation https://www.immunocore.com/investors/news/press-releases/detail/78/immunocore-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/77/immunocore-reports-third-quarter-2023-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/76/immunocore-announces-upcoming-poster-presentations-at-sitc-annual-meeting-2023-and-smr-congress-2023 https://www.immunocore.com/investors/news/press-releases/detail/75/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/74/immunocore-presents-three-year-overall-survival-data-from-the-kimmtrak-phase-3-trial https://www.immunocore.com/investors/news/press-releases/detail/73/immunocore-announces-upcoming-presentation-and-posters-at-esmo-2023 https://www.immunocore.com/investors/news/press-releases/detail/72/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/71/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/70/immunocore-reports-second-quarter-2023-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/69/immunocore-to-report-second-quarter-2023-financial-results-and-host-call-on-august-10-2023 https://www.immunocore.com/investors/news/press-releases/detail/5/immunocore-presents-additional-ctdna-data-from-the-kimmtrak-phase-3-trial-at-asco https://www.immunocore.com/investors/news/press-releases/detail/6/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/7/immunocore-reports-first-quarter-2023-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/8/immunocore-to-present-at-the-bank-of-america-securities-2023-health-care-conference https://www.immunocore.com/investors/news/press-releases/detail/9/immunocore-presents-new-kimmtrak-data-confirming-association-between-early-ctdna-reduction-and-longer-overall-survival https://www.immunocore.com/investors/news/press-releases/detail/10/immunocore-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/11/immunocore-to-present-four-posters-at-aacr-annual-meeting-2023 https://www.immunocore.com/investors/news/press-releases/detail/12/immunocore-reports-2022-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/13/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/14/immunocore-to-report-fourth-quarter-and-full-year-2022-earnings-and-host-call-on-march-1-2023 https://www.immunocore.com/investors/news/press-releases/detail/15/immunocore-announces-initial-phase-1-safety-and-pharmacodynamic-activity-data-with-first-soluble-tcr-therapy-for-people-living-with-hiv https://www.immunocore.com/investors/news/press-releases/detail/16/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/17/immunocore-announces-strategic-priorities-including-pipeline-expansion-for-2023--2024 https://www.immunocore.com/investors/news/press-releases/detail/18/immunocore-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/19/immunocore-is-awarded-the-prix-galien-france-award-for-kimmtrak https://www.immunocore.com/investors/news/press-releases/detail/20/immunocore-presents-ovarian-cancer-expansion-data-for-immtac-candidate-imc-c103c-targeting-mage-a4 https://www.immunocore.com/investors/news/press-releases/detail/21/immunocore-and-gadeta-announce-agreement-to-develop-first-gamma-delta-tcr-immtac-for-solid-tumors https://www.immunocore.com/investors/news/press-releases/detail/22/immunocore-to-present-at-the-5th-annual-evercore-isi-healthconx-conference https://www.immunocore.com/investors/news/press-releases/detail/23/immunocore-presents-new-biomarker-analysis-for-kimmtrak-tebentafusp-tebn-in-metastatic-uveal-melanoma-at-the-sitc-2022-annual-meeting https://www.immunocore.com/investors/news/press-releases/detail/24/immunocore-to-present-at-the-jefferies-london-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/25/immunocore-reports-third-quarter-2022-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/26/immunocore-presents-promising-initial-phase-1-data-for-first-off-the-shelf-tcr-therapy-targeting-prame-at-the-esmo-2022-congress https://www.immunocore.com/investors/news/press-releases/detail/27/immunocore-reports-second-quarter-2022-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/28/immunocore-to-report-second-quarter-2022-earnings-and-host-call-on-august-10-2022 https://www.immunocore.com/investors/news/press-releases/detail/29/immunocore-announces-upcoming-oral-presentation-of-initial-phase-1-data-of-immtac-candidate-imc-f106c-targeting-prame-at-european-society-for-medical-oncology-esmo-congress-2022 https://www.immunocore.com/investors/news/press-releases/detail/30/immunocore-announces-140-million-private-placement-financing https://www.immunocore.com/investors/news/press-releases/detail/31/immunocore-announces-dosing-of-first-patient-with-immtav-bispecific-for-hiv https://www.immunocore.com/investors/news/press-releases/detail/32/immunocore-announces-the-presentation-of-initial-data-from-the-phase-1-immtav-trial-for-chronic-hepatitis-b-at-the-easl-international-liver-congress https://www.immunocore.com/investors/news/press-releases/detail/33/immunocore-appoints-siddharth-kaul-to-its-board-of-directors https://www.immunocore.com/investors/news/press-releases/detail/34/the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-australian-therapeutic-goods-administration-tga-and-health-canada-approve-kimmtrak-tebentafusp-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma https://www.immunocore.com/investors/news/press-releases/detail/35/immunocore-presents-new-data-on-kimmtrak-tebentafusp-tebn-in-metastatic-cutaneous-mcm-and-uveal-melanoma-mum-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting https://www.immunocore.com/investors/news/press-releases/detail/36/immunocore-announces-clinical-trial-collaboration-with-sanofi-to-evaluate-sanofis-product-candidate-sar444245-non-alpha-il-2-in-combination-with-kimmtrak-in-patients-with-metastatic-cutaneous-melanoma https://www.immunocore.com/investors/news/press-releases/detail/37/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/38/immunocore-announces-upcoming-presentations-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting https://www.immunocore.com/investors/news/press-releases/detail/39/immunocore-reports-first-quarter-2022-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/40/immunocore-to-present-at-the-21st-annual-needham-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/41/european-commission-approves-kimmtrak-tebentafusp-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma https://www.immunocore.com/investors/news/press-releases/detail/42/immunocore-to-present-at-oppenheimers-32nd-annual-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/43/immunocore-reports-full-year-2021-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/44/immunocore-receives-positive-chmp-opinion-for-kimmtrak-tebentafusp-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma https://www.immunocore.com/investors/news/press-releases/detail/45/immunocore-to-present-at-the-svb-leerink-global-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/46/immunocore-announces-fda-approval-of-kimmtrak-tebentafusp-tebn-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma https://www.immunocore.com/investors/news/press-releases/detail/47/immunocore-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/48/immunocore-announces-initial-phase-1-data-of-immtac-candidate-imc-c103c-targeting-mage-a4 https://www.immunocore.com/investors/news/press-releases/detail/49/immunocore-to-present-at-the-jefferies-london-healthcare-conference https://www.immunocore.com/investors/news/press-releases/detail/50/immunocore-reports-third-quarter-2021-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/51/immunocore-presents-new-data-on-tebentafusp-in-metastatic-cutaneous-melanoma-mcm-and-uveal-melanoma-mum-at-the-society-for-immunotherapy-of-cancer-sitc-36th-annual-meeting https://www.immunocore.com/investors/news/press-releases/detail/52/immunocore-and-medison-pharma-partner-for-future-commercialization-of-tebentafusp-in-canada-central-eastern-europe-and-israel https://www.immunocore.com/investors/news/press-releases/detail/53/immunocore-announces-publication-of-phase-3-data-comparing-tebentafusp-with-investigators-choice-in-the-new-england-journal-of-medicine https://www.immunocore.com/investors/news/press-releases/detail/54/immunocore-presents-data-at-the-european-society-for-medical-oncology-esmo-congress-2021-demonstrating-a-reduction-in-circulating-tumor-dna-ctdna-while-on-tebentafusp-is-associated-with-overall-survival-in-the-phase-2-clinical-trial https://www.immunocore.com/investors/news/press-releases/detail/55/immunocore-announces-upcoming-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2021 https://www.immunocore.com/investors/news/press-releases/detail/56/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/57/immunocore-announces-uks-medicines-and-healthcare-products-regulatory-agency-mhra-accepts-marketing-authorization-application-for-tebentafusp-in-metastatic-uveal-melanoma https://www.immunocore.com/investors/news/press-releases/detail/58/immunocore-announces-that-u-s-food-and-drug-administration-and-european-medicines-agency-accept-biologics-license-application-and-marketing-authorization-application-for-tebentafusp-in-metastatic-uveal-melanoma https://www.immunocore.com/investors/news/press-releases/detail/59/immunocore-reports-second-quarter-2021-financial-results-and-provides-business-update https://www.immunocore.com/investors/news/press-releases/detail/60/immunocore-presents-clinical-data-further-characterizing-the-overall-survival-benefit-of-tebentafusp-in-metastatic-uveal-melanoma-at-the-2021-american-society-of-clinical-oncology-asco-annual-meeting https://www.immunocore.com/investors/news/press-releases/detail/61/immunocore-to-present-at-upcoming-investor-conferences https://www.immunocore.com/investors/news/press-releases/detail/62/immunocore-announces-dosing-of-first-patient-with-immtav-bispecific-molecule-for-chronic-hepatitis-b https://www.immunocore.com/investors/news/press-releases/detail/63/immunocore-reports-first-quarter-2021-financial-results https://www.immunocore.com/investors/news/press-releases/detail/64/immunocore-announces-upcoming-presentations-at-the-2021-american-society-of-clinical-oncology-asco-annual-meeting https://www.immunocore.com/investors/news/press-releases/detail/65/immunocore-presents-phase-3-data-comparing-tebentafusp-with-investigators-choice-in-the-clinical-trial-plenary-session-at-the-american-association-for-cancer-research-2021-annual-meeting https://www.immunocore.com/investors/news/press-releases/detail/66/immunocore-provides-business-update-and-reports-full-year-2020-financial-results https://www.immunocore.com/investors/news/press-releases/detail/67/immunocore-announces-upcoming-presentations-at-the-american-association-for-cancer-research-aacr-2021-annual-meeting https://www.immunocore.com/investors/news/press-releases/detail/68/immunocores-tebentafusp-granted-breakthrough-therapy-designation-for-unresectable-or-metastatic-uveal-melanoma-from-fda https://www.immunocore.com/disclaimer https://www.immunocore.com/sitemap https://www.immunocore.com/about-us/compliance-and-transparency